COMMUNIQUÉS West-GlobeNewswire

Hormonic Unveils All-in-One Platform to Revolutionize Women’s Hormonal Health
31/10/2024
Hormonic offers personalized hormone health care through telehealth services and high-quality natural supplements, targeting root causes of imbalances Munich, Germany, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Hormonic is proud [...]
WAKE RADIOLOGY TO HOST LUNG CANCER SCREENING EVENT SATURDAY, NOVEMBER 9
31/10/2024
Raleigh, N.C., Oct. 31, 2024 (GLOBE NEWSWIRE) -- On Saturday, November 9, Wake Radiology UNC Health Rex, in partnership with the American College of Radiology, is participating in National Lung Cancer Screening Day, [...]
Psyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs
31/10/2024
PsyLabs develops and produces certified pharmaceutical-grade nature-derived psychedelics for applications in mental health and well-being Psyence Biomedical has issued common shares to Psyence Group pursuant to a debt- [...]
HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024
31/10/2024
Society of Immunotherapy of Cancer (SITC) poster to be presented by collaborator from Memorial Sloan Kettering Cancer Center, Dr. Alan Ho, on November 9, 2024 NEW YORK and VIENNA, Oct. 31, 2024 (GLOBE NEWSWIRE) -- [...]
Sanara MedTech Inc. Announces Third Quarter Earnings Release and Conference Call Dates
31/10/2024
FORT WORTH, TX, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Sanara MedTech Inc . Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused [...]
Dogwood Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Thursday, November 7, 2024
31/10/2024
ATLANTA, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), formerly Virios Therapeutics, Inc., a clinical‐stage biopharmaceutical company, announced today that it will report [...]
MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors
31/10/2024
NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics (MiNK, NASDAQ: INKT), a clinical-stage company pioneering the development of allogeneic off-the-shelf, invariant natural killer T (iNKT) cell therapies, [...]
NAYA Biosciences to Present Translational Insights to Support Phase I/IIa Clinical Trials for its GPC3-Targeting NK Engager Bispecific Antibody at the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
31/10/2024
Abstracts demonstrate reversal of resistance to PD1 checkpoint blockade and predictive AI model of HCC survival rate SARASOTA, Fla. and MIAMI, Oct. 31, 2024 (GLOBE NEWSWIRE) -- NAYA Biosciences (“NAYA”) (NASDAQ: NAYA), [...]
Sharecare expands suite of interactive media solutions to engage, educate, and activate patients and providers
31/10/2024
Six new solutions help elevate health literacy, close communication gaps between patients and providers, and drive measurable impact for life sciences brands ATLANTA, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Sharecare, the [...]
HMNC Brain Health to Present Advances in Precision Psychiatry and Psychedelics at CNS Summit 2024 in Boston
31/10/2024
Company Leaders To Contribute to Key Discussions On The Future Of Mental Health Treatment, Unveiling Innovations In Genetic Companion Diagnostics And Psychedelic Therapies MUNICH, Oct. 31, 2024 (GLOBE NEWSWIRE) -- HMNC [...]
e-therapeutics Announces Business Updates and Interim Results
31/10/2024
LONDON, Oct. 31, 2024 (GLOBE NEWSWIRE) -- e-therapeutics plc, a company integrating computational power and biological data to discover life-transforming RNAi medicines, today announced business updates, including its [...]
Guardion Health Sciences Announces Filing of Certificate of Dissolution
30/10/2024
HOUSTON, TEXAS, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”) today announced that it has filed a certificate of dissolution with the Secretary of State of [...]
ANI Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 8, 2024, at 8:00 a.m. ET
30/10/2024
PRINCETON, N.J., Oct. 30, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its third quarter 2024 financial results on Friday, [...]
23andMe Regains Compliance With Nasdaq Listing Requirements
30/10/2024
SUNNYVALE, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (the “Company” or “23andMe”), a leading human genetics and preventive health company, today announced that the Company has regained [...]
Wave Life Sciences Highlights Growing Pipeline at Research Day, including INHBE siRNA Program for Obesity and New RNA Editing Programs
30/10/2024
WVE-007 (INHBE GalNAc-siRNA for obesity) is on track to initiate a clinical trial in 1Q 2025; new preclinical data for WVE-007 demonstrate opportunities for monotherapy, for synergistic use with GLP-1s, and for [...]
Septerna Announces Closing of $331.2 Million Upsized Initial Public Offering
30/10/2024
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug [...]
Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024
30/10/2024
NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell [...]
Cellectis publiera ses résultats financiers du troisième trimestre 2024 le 4 novembre 2024
30/10/2024
NEW YORK, 30 oct. 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique qui utilise sa technologie pionnière d’édition du génome TALEN® pour développer [...]
STERIS Declares Dividend of $0.57 per share
30/10/2024
DUBLIN, IRELAND, Oct. 30, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly interim dividend of $0.57 per share. The dividend is [...]

Pages